Table 3 Hazard ratio for new-onset diabetes, according to subgroup
Subgroup | No. of patients | Statin users | Non-users | Hazard ratio | P value for interaction | |
|---|---|---|---|---|---|---|
| Â | Â | Â | No. of events (%) | (95% CI) | ||
All patients | 1000 | 78 (15.6) | 48 (9.6) | 1.61 (1.10–2.37) |  | |
Age | ||||||
  < 65 yr | 596 | 46 (14.1) | 22 (8.2) | 1.52 (0.90–2.58) | 0.8219 | |
  ≥ 65 yr | 404 | 32 (18.4) | 26 (11.3) | 1.67 (0.93–2.99) |  | |
Sex | ||||||
 Female | 581 | 39 (13.7) | 25 (8.4) | 1.66 (0.94–2.92) | 0.9035 | |
 Male | 431 | 38 (17.1) | 22 (10.5) | 1.58 (0.94–2.66) |  | |
Medical history | ||||||
Cerebrovascular disease | ||||||
 Yes | 151 | 13 (17.3) | 9 (11.8) | 1.00 (0.37–2.66) | 0.2935 | |
 No | 849 | 65 (15.3) | 39 (9.2) | 1.77 (1.17–2.70) |  | |
Ischemic heart disease | ||||||
 Yes | 217 | 29 (25.2) | 12 (11.8) | 2.28 (1.11–4.66) | 0.2279 | |
 No | 783 | 49 (12.7) | 36 (9.1) | 1.34 (0.84–2.14) |  | |
Other heart disease | ||||||
 Yes | 213 | 25 (22.3) | 12 (11.9) | 1.59 (0.78–3.24) | 0.9372 | |
 No | 787 | 53 (13.7) | 36 (9.0) | 1.54 (0.97–2.44) |  | |
Liver disease | ||||||
 Yes | 136 | 4 (5.9) | 6 (8.8) | 1.45 (0.65–3.27) | 0.7781 | |
 No | 864 | 74 (9.7) | 42 (9.7) | 1.65 (1.10–2.44) |  | |
Hypertension | ||||||
 Yes | 450 | 44 (18.9) | 26 (12.0) | 1.57 (0.87–2.81) | 0.9993 | |
 No | 550 | 34 (12.7) | 22 (7.8) | 1.57 (0.87–2.64) |  | |
Medication | ||||||
ARB use | ||||||
 Yes | 410 | 39 (18.1) | 22 (11.3) | 1.31 (0.78–2.21) | 0.2802 | |
 No | 590 | 39 (13.7) | 26 (8.5) | 1.87 (1.16–3.01) |  | |
CCB use | ||||||
 Yes | 222 | 25 (22.7) | 13 (11.6) | 1.31 (0.70–2.46) | 0.4316 | |
 No | 778 | 53 (13.6) | 35 (9.0) | 1.72 (1.13–2.63) |  | |
Beta blocker use | ||||||
 Yes | 244 | 23 (18.6) | 12 (10.0) | 1.61 (0.84–3.08) | 0.9948 | |
 No | 756 | 55 (14.6) | 36 (9.5) | 1.62 (1.06–2.47) |  | |
Other antihypertensive drug use | ||||||
 Yes | 68 | 8 (22.9) | 5 (15.2) | 0.84 (0.33–2.12) | 0.1378 | |
 No | 932 | 70 (15.1) | 43 (9.2) | 1.71 (1.15–2.54) |  | |
Antithrombotic drug use | ||||||
 Yes | 114 | 11 (19.3) | 9 (15.8) | 1.15 (0.41–3.20) | 0.4685 | |
 No | 886 | 67 (15.1) | 39 (8.8) | 1.73 (1.14–2.63) |  | |
Proton pump inhibitor use | ||||||
 Yes | 375 | 36 (19.8) | 26 (13.5) | 1.40 (0.80–2.43) | 0.5513 | |
 No | 625 | 42 (13.2) | 22 (7.2) | 1.89 (1.09–3.27) |  | |
H2 blocker use | ||||||
 Yes | 260 | 24 (18.6) | 17 (13.0) | 1.57 (0.77–3.21) | 0.8787 | |
 No | 740 | 54 (14.6) | 31 (8.4) | 1.68 (1.06–2.66) |  | |
NSAID use | ||||||
 Yes | 171 | 26 (28.3) | 10 (12.7) | 2.95 (1.36–6.39) | 0.0786 | |
 No | 829 | 52 (12.8) | 38 (9.0) | 1.31 (0.83–2.06) |  | |
Non-thiazide diuretic use | ||||||
 Yes | 135 | 14 (23.3) | 9 (12.9) | 1.38 (0.52–3.70) | 0.7361 | |
 No | 870 | 64 (14.5) | 39 (9.1) | 1.66 (1.10–2.51) |  | |
Antiarrhythmic drug use | ||||||
 Yes | 69 | 6 (17.1) | 7 (20.6) | 0.67 (0.19–2.42) | 0.1553 | |
 No | 931 | 72 (15.4) | 41 (8.8) | 1.78 (1.19–2.68) |  | |